Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2021

View Archived Issues

Enrollment opens in phase IIa study of MK-1942 in treatment-resistant depression

Aprea begins enrollment in first-in-human study of APR-548 for TP53-mutated MDS

Prime, base editing are "finer scalpels" in dystrophy

APVO-442: a bispecific T-cell engager targeting PSMA and CD3 for treating prostate cancer

Proof of concept demonstrated with ABX-002 prodrug brain delivery of thyromimetic LL-340001

Zenshine compounds targeting E-NPP 1 have antitumor activity

Vaxart initiates enrollment in phase Ib boosting regimen trial of its norovirus vaccine

Revolo presents encouraging safety data for its peptide drug for allergic disease

Incyte discloses new CDK2/cyclin E inhibitors

BeiGene synthesizes STING modulators

BioCryst Pharmaceuticals presents complement factor D inhibitors

Cellectar Biosciences describes new phospholipid-drug conjugates for cancer

First healthy volunteers dosed in phase I/II study of HDT Bio's COVID-19 RNA vaccine in India

Fate Therapeutics patents new CARs for cancer immunotherapy

Betacellulin is a novel therapeutic target in schizophrenia

Positive topline data from GENESIS phase III study of motixafortide plus G-CSF in multiple myeloma

Kiniksa reports final data from first-in-human trial of KPL-404

New mutations in the SETX gene tied to ataxia with oculomotor apraxia type 2

Ascletis reports phase IIa data on ASC-22 for chronic hepatitis B

FDA clears IND for phase I/II study of Clarity's prostate cancer theranostic products

European Commission approves Sibnayal for distal renal tubular acidosis

Preclinical characterization of novel small molecule inhibitor of CD38, RBN-013209

SOM-3355 reduces chorea in patients with HD

Tecentriq approved in E.U. for first-line metastatic NSCLC with high PD-L1 expression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...